Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
infoIterum Therapeutics is a micro cap stock with a total market cap of 12.91M.
infoThey trade on the NASDAQ and had their IPO 5 years and 2 months ago.
infoIterum Therapeutics currently employs 14 people.
infoAs of Wednesday, Aug 23 2023, Iterum Therapeutics’s share price is $0.92.
News Relating to Iterum Therapeutics
GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
Friday Aug 04 2023 at 17:00
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
GlobeNewsWire
Iterum Therapeutics to Present Data at ASM Microbe 2023
Monday Jun 12 2023 at 18:23
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.
Zacks Investment Research
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
Thursday Apr 13 2023 at 13:39
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Thursday Mar 09 2023 at 17:00
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
Seeking Alpha
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
Thursday Nov 10 2022 at 11:42
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call.
GlobeNewsWire
Iterum Therapeutics to Present Data at IDWeek 2022
Monday Oct 17 2022 at 17:19
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.
GlobeNewsWire
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Wednesday Sep 07 2022 at 09:15
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm(ET) on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022.
Pulse2
Iterum Therapeutics (ITRM) Stock: 1-For-15 Reverse Split Goes Into Effect
Thursday Aug 18 2022 at 08:42
A 1-for-15 reverse split of Iterum Therapeutics (ITRM) shares have gone into effect. These are the details.
GlobeNewsWire
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
Tuesday Aug 16 2022 at 21:00
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022.
Benzinga
Iterum Therapeutics Shares Are Surging – Read Why
Monday Jul 11 2022 at 14:40
Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections. The pivotal.
InvestorPlace
Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?
Monday Jul 11 2022 at 11:14
Iterum Therapeutics (ITRM) stock is taking off on Monday as investors react to news of a clinical trial agreement with the FDA. The post Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?
PennyStocks
Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch
Monday Jul 11 2022 at 09:25
More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Seeking Alpha
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2021 Results – Earnings Call Transcript
Monday Mar 28 2022 at 10:53
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2021 Results – Earnings Call Transcript
PennyStocks
Hot Penny Stocks to Watch in Early February 2022
Thursday Feb 03 2022 at 13:50
Why investors are watching these penny stocks right now The post Hot Penny Stocks to Watch in Early February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
3 Reddit Penny Stocks to Watch in December 2021
Tuesday Nov 23 2021 at 16:46
Are these Reddit penny stocks on your watchlist right now? The post 3 Reddit Penny Stocks to Watch in December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here’s Why You Should Buy the Stock Now
Monday Nov 22 2021 at 11:30
Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
Seeking Alpha
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q3 2021 Results – Earnings Call Transcript
Friday Nov 12 2021 at 10:57
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q3 2021 Results – Earnings Call Transcript
PennyStocks
Top Penny Stocks For Your List Today? Check These 4 Out
Tuesday Nov 09 2021 at 10:30
Are these penny stocks on your watchlist right now? The post Top Penny Stocks For Your List Today?
GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
Friday Nov 05 2021 at 07:00
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
PennyStocks
Hot Penny Stocks You Need to Know About Right Now
Monday Oct 18 2021 at 09:19
Looking for penny stocks to watch right now? Check these three out The post Hot Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Newsfile Corp
ITRM LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Iterum Therapeutics Plc
Monday Oct 04 2021 at 14:58
New York, New York–(Newsfile Corp. – October 4, 2021) – The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Iterum Therapeutics Plc (“Iterum”) (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=20109&wire=5
Newsfile Corp
Last Few Hours for Investors to Actively Participate in Iterum Therapeutics plc (ITRM) Class Action – Bronstein, Gewirtz & Grossman, LLC
Monday Oct 04 2021 at 10:00
New York, New York–(Newsfile Corp. – October 4, 2021) – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Iterum Therapeutics plc (“Iterum” or “the Company”) (NASDAQ: ITRM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Iterum securities between November 30, 2020 and July 23, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s…
Newsfile Corp
ITRM Final Deadline Today: Rosen, National Trial Lawyers, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
Monday Oct 04 2021 at 08:36
New York, New York–(Newsfile Corp. – October 4, 2021) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021, inclusive (the “Class Period”), of the important October 4, 2021 lead plaintiff deadline.SO WHAT: If you purchased Iterum securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees…
Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 – ITRM
Monday Oct 04 2021 at 05:34
New York, New York–(Newsfile Corp. – October 4, 2021) – The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Iterum Therapeutics Plc (NASDAQ: ITRM) (“Iterum”) between November 30, 2020 and July 23, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois. To get more information go to:https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=20083&wire=5or…
Accesswire
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATVI, ITRM and KPLT
Sunday Oct 03 2021 at 10:20
NEW YORK, NY / ACCESSWIRE / October 3, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
Newsfile Corp
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Iterum Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – ITRM
Friday Oct 01 2021 at 15:09
New York, New York–(Newsfile Corp. – October 1, 2021) – Pomerantz LLP announces that a class action lawsuit has been filed against Iterum Therapeutics plc (“Iterum” or the “Company”) (NASDAQ: ITRM) and certain of its officers. The class action, filed in the United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 21-cv-04181, is on behalf of a class consisting of all persons and entities other than…
Business Wire
Monday Deadline for Investors to Actively Participate in Iterum Therapeutics plc (ITRM) Class Action – Bronstein, Gewirtz & Grossman, LLC
Friday Oct 01 2021 at 11:00
NEW YORK–(BUSINESS WIRE)–Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Iterum Therapeutics plc (“Iterum” or “the Company”) (NASDAQ: ITRM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Iterum securities between November 30, 2020 and July 23, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.
Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 – ITRM
Friday Oct 01 2021 at 09:13
New York, New York–(Newsfile Corp. – October 1, 2021) – The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Iterum Therapeutics Plc (“Iterum”) (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois. To get more information…
Newsfile Corp
ITRM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Iterum Therapeutics Plc Limited Shareholders
Friday Oct 01 2021 at 05:22
New York, New York–(Newsfile Corp. – October 1, 2021) – The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Iterum Therapeutics Plc (NASDAQ: ITRM) alleging that the Company violated federal securities laws.Class Period: November 30, 2020 and July 23, 2021Lead Plaintiff Deadline: October 4, 2021No obligation or cost to you.Learn more about your recoverable losses in ITRM:https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=20032&from=5
Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 – ITRM
Thursday Sep 30 2021 at 05:21
New York, New York–(Newsfile Corp. – September 30, 2021) – The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Iterum Therapeutics Plc (NASDAQ: ITRM) (“Iterum”) between November 30, 2020 and July 23, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois. To get more information go to:https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19992&wire=5or…
Iterum Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Iterum Therapeutics’s Altman Z-score is -13.39 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Iterum Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Iterum Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Iterum Therapeutics’s Income Quality of 0.33 is lower than its Industry Group of 0.69 (-52.2% lower)
Iterum Therapeutics’s Income Quality of 0.33 is lower than its Major Industry Group of 0.71 (-53.5% lower)
Iterum Therapeutics’s Income Quality of 0.33 is lower than its Sector of 0.75 (-56.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Iterum Therapeutics’s Current Ratio of 4.4 is in line with its Industry Group of 4.76 (-7.6% lower)
Iterum Therapeutics’s Current Ratio of 4.4 is in line with its Major Industry Group of 4.32 (1.9% greater)
Iterum Therapeutics’s Current Ratio of 4.4 is greater than its Sector of 2.6 (69.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.23 & -1.27)
Cannot compare a negative PE Ratio (-0.23 & -1.1)
Cannot compare a negative PE Ratio (-0.23 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Iterum Therapeutics’s PB Ratio of 1.81 is greater than its Industry Group of 1.34 (35.1% greater)
Iterum Therapeutics’s PB Ratio of 1.81 is greater than its Major Industry Group of 1.4 (29.3% greater)
Iterum Therapeutics’s PB Ratio of 1.81 is greater than its Sector of 1.62 (11.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Iterum Therapeutics’s ROE of -7.9 is lower than its Industry Group of -0.44 (-1695.5% lower)
Iterum Therapeutics’s ROE of -7.9 is lower than its Major Industry Group of -0.38 (-1978.9% lower)
Iterum Therapeutics’s ROE of -7.9 is lower than its Sector of -0.03 (-26233.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Iterum Therapeutics’s ROCE of -0.89 is lower than its Industry Group of -0.42 (-111.9% lower)
Iterum Therapeutics’s ROCE of -0.89 is lower than its Major Industry Group of -0.37 (-140.5% lower)
Iterum Therapeutics’s ROCE of -0.89 is lower than its Sector of -0.04 (-2125.0% lower)
Derived from SEC.GOV filing dataopen_in_new